Connect with us

Heroes

One-Time CRISPR Infusion Cuts Bad Cholesterol by Half, Lasting Over a Year

Published

on

Quick Smiles:

  • Single gene-editing infusion slashes LDL cholesterol by 52 percent in first human trial
  • Patients still show the benefit a full year later with zero reported side effects
  • Researchers at Cleveland Clinic call the results a hopeful step toward simpler heart-health care

Doctors at Cleveland Clinic have just completed the world’s first human trial of a one-time CRISPR therapy aimed at lowering dangerously high cholesterol, and the early numbers are nothing short of inspiring.

After a single infusion, participants saw their LDL—or “bad”—cholesterol drop by an average of 52 percent, with the improvement still holding strong twelve months later.

“We are seeing sustained, clinically meaningful reductions without the need for ongoing medication,” the research team shared.

The treatment uses CRISPR-Cas9 to briefly turn off a liver gene that interferes with clearing LDL from the bloodstream, offering a potential alternative for people who struggle with daily statins or frequent injections.

Importantly, no serious side effects have been observed so far, giving families renewed hope that heart-health solutions can be simpler and kinder.

“It’s the kind of result that reminds us science can still deliver good news,” one participant noted.

Advertisement

While larger studies are underway, this early success already feels like a heart-warming glimpse of a future where one gentle treatment could protect countless hearts for years to come.

Source

Advertisement
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending